UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

Benzinga · 2d ago
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.